Last updated: July 27, 2025
Introduction
South Korean Patent KR20140148459, filed by Hanmi Pharmaceutical Co., Ltd., pertains to a novel pharmaceutical composition and its method of use, specifically focusing on a method for treating or preventing diseases associated with obesity and metabolic syndrome. This patent exemplifies the strategic innovation in the arena of metabolic disorder therapeutics, emphasizing a focused claim set to protect novel combinations, formulations, or mechanisms of action.
This comprehensive analysis explores the scope of KR20140148459, reviews its claims in detail, evaluates its strategic position within the patent landscape, and discusses implications for competitors and licensors in the pharmaceutical sector.
Patent Overview and Filing Context
KR20140148459 was filed on July 1, 2014, with the Korean Intellectual Property Office (KIPO), targeting innovative therapeutic interventions for obesity-related disorders. The patent aims to safeguard a novel composition comprising specific active ingredients or formulations that effectively address metabolic syndrome, including insulin resistance, dyslipidemia, and adiposity.
The patent's strategic importance depends heavily on its claims' breadth, novelty, inventive step, and relevance within the existing patent landscape in both South Korea and globally.
Scope of the Patent
The scope of KR20140148459 primarily hinges on the specific claims, which define the monopoly granted over its inventive subject matter. The scope can be broadly classified into:
- Composition claims: Covering the specific pharmaceutical formulations with defined active ingredients.
- Method claims: Encompassing the therapeutic methods for treating or preventing obesity-related diseases.
- Use claims: Covering the novel application of known compounds or compositions for specific indications.
Key Elements of the Scope:
-
Active Ingredient Specifics: The patent claims often specify certain compounds—potentially novel dual or multi-target agents targeting metabolic pathways, such as GLP-1 receptor agonists, PPAR modulators, or combination therapies.
-
Formulation Aspects: Claims could extend to specific dosage forms, nanocarriers, sustained-release systems, or combination ratios that enhance bioavailability or efficacy.
-
Method of Use: Therapeutic claims typically specify methods involving administration of the composition to patients exhibiting obesity or metabolic disorders, including criteria for treatment efficacy.
-
Synergistic Combinations: If explicitly claimed, combinations of known agents with new dosing regimens or delivery methods expand scope.
Claims Analysis
The claims underpin the legal scope and enforceability of the patent. While the exact language of KR20140148459's claims can only be precisely analyzed through the official patent document, typical claims in such patents include:
1. Composition Claims
- Broadly claiming pharmaceutical compositions comprising at least one active ingredient capable of modulating metabolic pathways associated with obesity (e.g., GLP-1 receptor activation, PPAR modulation).
- Dependent claims specify particular active ingredients, combinations, or dosage forms.
2. Method of Treatment Claims
- Claiming a method of reducing body weight or controlling obesity-related symptoms, involving administering a therapeutically effective amount of the composition.
- Possible inclusion of patient subsets—e.g., those with insulin resistance or dyslipidemia.
3. Use Claims
- Claiming the use of the composition for manufacturing a medicament for obesity or metabolic syndrome.
4. Formulation Claims
- Specific claims about formulations—e.g., sustained-release tablets, injectable forms, or combination delivery systems—that improve pharmacokinetics.
Analysis:
- Breadth vs. Specificity: If the composition claims are broad, covering classes of compounds or functional equivalents, they provide extensive protection but face challenges related to obviousness or lack of novelty.
- Dependent claims: Refine and reinforce the scope by specifying compounds, combinations, or device features, making it easier to enforce and defend.
- Method and use claims: These are crucial for targeting therapeutic indications but generally face restrictions against prior art and require clear inventive steps.
Patent Landscape Context
1. Global Patent Environment
- Prior Art and Similar Patents: The patent landscape around obesity and metabolic disorder medications is dense, with key players including Novo Nordisk, Eli Lilly, and Biocon involved in GLP-1 receptor agonists, PPAR modulators, and combination therapies.
- Existing Patents: Numerous patents cover individual agents, formulations, and methods. KR20140148459 likely builds on existing knowledge but aims for novelty in specific combinations or formulations.
2. Key Competitors and Patent Overlaps
- Competitor Patents: Many patents target incretin mimetics, insulin sensitizers, or dual-action agents.
- Potential Overlaps: Composition claims that encompass known agents in known combinations could face validity challenges if they lack inventive step; however, novel formulations or specific method claims could provide robust protection.
3. Citation and Litigation Trends
- The patent's forward citations from subsequent patents in the metabolic disorder space could indicate its influence.
- Enforceability depends on the novelty and inventive step over prior art, especially given high patenting activity in this area.
4. Geographical Considerations
- Parallel filings in Japan, Europe, and the US are common; KR20140148459's protection may be reinforced if similar filings claim priority or are linked via patent family strategies.
Strategic Implications
- The scope’s breadth implies potential for market exclusivity in specific formulations and therapeutic methods.
- The patent can serve as a basis to develop combination therapies, especially if the claims are broad enough to prevent third-party development of similar compositions.
- The scope’s limitations are primarily dictated by prior art constraints, thus emphasizing the importance of narrow, inventive claims.
Legal and Commercial Considerations
- Patent Validity: Challenged by prior art, especially for composition claims involving known compounds.
- Infringement Risks: Competitors designing around specific claims or developing alternative formulations can circumvent patent rights.
- Patent Life: Typically 20 years from filing; although patent term adjustments may apply, maintaining market exclusivity in synergistic therapeutic areas is crucial.
Conclusion
KR20140148459 exemplifies a strategic effort by Hanmi Pharmaceuticals to carve out a niche within metabolic disorder therapeutics via specific novel compositions and methods. Its scope, primarily defined by claims related to active ingredients, formulations, and therapeutic methods, seeks to balance broad protection with defensibility against prior art.
In the increasingly crowded landscape of obesity and metabolic syndrome patents, the patent’s enforceability and value depend on the novelty of the specific claims and their execution. Its strategic positioning can provide a competitive edge in South Korea and possibly in international markets through patent family expansion.
Key Takeaways
- Broad yet specific claims enhance patent protection but must be balanced against prior art to ensure validity.
- Combination therapies and formulation innovations are central to maximizing scope and commercial value.
- Patent landscapes in metabolic disorder therapeutics are highly competitive; careful crafting of claims is critical.
- Enforcement and licensing strategies should target specific formulations and methods protected by the claims to mitigate infringement risks.
- International patent filing and coordination can extend protection, particularly when targeting global markets.
FAQs
1. What is the primary therapeutic focus of KR20140148459?
It targets obesity and related metabolic disorders through novel pharmaceutical compositions and therapeutic methods, potentially involving specific active ingredients and formulations.
2. How broad are the composition claims in KR20140148459?
While the exact claims are proprietary, such patents often claim a range of compositions involving active ingredients related to metabolic regulation, with dependent claims narrowing the scope to specific compounds or formulations.
3. Can this patent protect combination therapies?
Yes, if explicitly claimed, the patent can secure protection for combinations of agents used to treat obesity and metabolic syndrome, provided they meet novelty and inventive step criteria.
4. How does this patent fit into the global patent landscape?
KR20140148459 complements existing patents by focusing on specific formulations or methods not previously claimed, but it operates within a crowded space of metabolic disorder IP, requiring strategic management for global protection.
5. What are the risks of patent invalidation for KR20140148459?
Potential invalidation risks include prior art that discloses similar compositions, lack of inventive step, or claims that are overly broad and not adequately supported by data.
Sources
- Korean Intellectual Property Office (KIPO). Patent KR20140148459.
- Patent scope and claim analysis based on official patent document.
- Industry reports on metabolic disorder therapeutics (e.g., [1], [2]).
- Comparative patent landscape studies (e.g., [3]).
Note: For precise claim language and legal status, access to the official patent document through KIPO or patent databases such as WIPO or Espacenet is recommended.
